Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 4,084 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

ACCURATE Study for Subjects With Dry Eyes

NCT04237012
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Dextenza 0.4Mg Intracanalicular Insert, Over the counter Artificial tears
Drug · Other
Lead sponsor
The Eye Centers of Racine and Kenosha
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 13, 2026, 10:32 PM EDT
Terminated Phase 2 Interventional Results available

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

NCT04738292
View directory record Official record
Conditions
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Interventions
Onapristone, Fulvestrant
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

NCT00642018
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, LY2181308 sodium, Prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 13, 2026, 10:32 PM EDT
Terminated Not applicable Interventional Results available

Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study

NCT01608490
View directory record Official record
Conditions
Emphysema
Interventions
RePneu Lung Volume Reduction Coil System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
35 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 13, 2026, 10:32 PM EDT
Withdrawn Phase 4 Interventional

Detection of Diffuse Scar in Patients With Diabetes

NCT01794091
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 13, 2026, 10:32 PM EDT
Active, not recruiting Phase 1 Interventional

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

NCT02337985
View directory record Official record
Conditions
AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, HIV Infection, AIDS Related Non-Hodgkin Lymphoma
Interventions
Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Phase 4 Interventional

Perioperative Steroid Dosing on the APR in AIS

NCT05561725
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis (AIS)
Interventions
Dexamethasone postoperative, Standard of Care
Drug
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00713193
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Cyclosporine, Prednisone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Phase 4 Interventional Results available

Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach

NCT03382821
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
Transforaminal ESI with dexamethasone, Transforaminal catheter-targeted ESI with triamcinolone, Dexamethasone Sodium Phosphate 10 MG/ML, Lidocaine, Triamcinolone Acetonide 40mg/mL
Procedure · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 13, 2026, 10:32 PM EDT
Recruiting Phase 2 Interventional

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

NCT06974604
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms
Interventions
Dexamethasone oral
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Not applicable Interventional Results available

Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies

NCT05279898
View directory record Official record
Conditions
Postoperative Delirium, Hemodynamic Instability, Pain, Neurocognitive Dysfunction
Interventions
EEG Monitoring, Ropivacaine, Ketamine, Remifentanil, Dexmedetomidine, Rocuronium, Propofol
Device · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 13, 2026, 10:32 PM EDT
Active, not recruiting Phase 2 Interventional

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

NCT02949284
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Biological · Other + 1 more
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis

NCT01903798
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Mycophenolate mofetil, Prednisolone, Rilonacept
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Long Beach, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 13, 2026, 10:32 PM EDT
Recruiting Phase 1 Interventional

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

NCT06977711
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Phase 3 Interventional Results available

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

NCT00075764
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, fulvestrant
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
418
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 289 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00301821
View directory record Official record
Conditions
Lymphoma
Interventions
epratuzumab, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
162
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 102 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 13, 2026, 10:32 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

NCT05221021
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Vaginal estrogen, Mirabegron 50 MG [Myrbetriq]
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 13, 2026, 10:32 PM EDT
Withdrawn Phase 4 Interventional

Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis

NCT03245671
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Kenalog Injectable Product, Decadron Phosphate, Injectable, Epidural Steroid Injection
Drug · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 13, 2026, 10:32 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 13, 2026, 10:32 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

NCT06209606
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 13, 2026, 10:32 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

NCT01406197
View directory record Official record
Conditions
Preterm Labor
Interventions
Experimental: Vaginal progesterone, Experimental: Topical progesterone, Experimental: Intramuscular progesterone
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
17 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 13, 2026, 10:32 PM EDT
Recruiting Phase 2 Interventional

Spironolactone for Pulmonary Arterial Hypertension

NCT01712620
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 10:32 PM EDT
Not yet recruiting Phase 2 Interventional

Fluorometholone Study

NCT07308938
View directory record Official record
Conditions
Keratitis Bacterial, Corneal Ulcer (Diagnosis)
Interventions
Adjunctive Topical Fluorometholone (FML) 0.1%, Standard Topical Antibiotic Therapy
Drug
Lead sponsor
Vishal Jhanji
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 13, 2026, 10:32 PM EDT
Completed Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

NCT00617591
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 13, 2026, 10:32 PM EDT